Nautilus Biotechnology annual free cash flow
2020
2021
2022
2023
2024
2025
Nautilus Biotechnology Free Cash Flow (FCF) History (NAUT)
Nautilus Biotechnology reported −$52.0M in free cash flow for fiscal 2025, an increase of $9.3M from the previous fiscal year.
View full Nautilus Biotechnology company overviewNautilus Biotechnology free cash flow by year
| Fiscal year | Period ended | Free cash flow | Change | Growth | FCF margin |
|---|---|---|---|---|---|
| 2025 | 2025-12-31 | −$52.0M | $9.3M | — | — |
| 2024 | 2024-12-31 | −$61.3M | −$7.1M | — | — |
| 2023 | 2023-12-31 | −$54.2M | −$6.0M | — | — |
| 2022 | 2022-12-31 | −$48.1M | −$6.6M | — | — |
| 2021 | 2021-12-31 | −$41.5M | −$26.6M | — | — |
| 2020 | 2020-12-31 | −$14.9M | — | — | — |
Nautilus Biotechnology quarterly free cash flow
Q3.20
Q1.21
Q2.21
Q3.21
Q4.21
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q2.23
Q3.23
Q4.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
| Fiscal quarter | Period ended | Free cash flow | Change | YoY growth | FCF margin |
|---|---|---|---|---|---|
| Q1 2026 | 2026-03-31 | −$13.6M | $546,000 | — | — |
| Q4 2025 | 2025-12-31 | −$12.6M | $1.9M | — | — |
| Q3 2025 | 2025-09-30 | −$11.5M | $2.4M | — | — |
| Q2 2025 | 2025-06-30 | −$13.7M | $2.2M | — | — |
| Q1 2025 | 2025-03-31 | −$14.2M | $2.8M | — | — |
| Q4 2024 | 2024-12-31 | −$14.6M | −$250,000 | — | — |
| Q3 2024 | 2024-09-30 | −$13.8M | −$1.2M | — | — |
| Q2 2024 | 2024-06-30 | −$16.0M | −$2.0M | — | — |
| Q1 2024 | 2024-03-31 | −$16.9M | −$3.7M | — | — |
| Q4 2023 | 2023-12-31 | −$14.3M | −$3.7M | — | — |
| Q3 2023 | 2023-09-30 | −$12.6M | −$2.1M | — | — |
| Q2 2023 | 2023-06-30 | −$14.0M | $168,000 | — | — |
| Q1 2023 | 2023-03-31 | −$13.2M | −$400,000 | — | — |
| Q4 2022 | 2022-12-31 | −$10.6M | $899,000 | — | — |
| Q3 2022 | 2022-09-30 | −$10.5M | $3.9M | — | — |
| Q2 2022 | 2022-06-30 | −$14.2M | −$5.4M | — | — |
| Q1 2022 | 2022-03-31 | −$12.8M | −$6.1M | — | — |
| Q4 2021 | 2021-12-31 | −$11.5M | −$10.8M | — | — |
| Q3 2021 | 2021-09-30 | −$14.4M | — | — | — |
| Q2 2021 | 2021-06-30 | −$8.8M | — | — | — |
| Q1 2021 | 2021-03-31 | −$6.7M | — | — | — |
| Q3 2020 | 2020-09-30 | −$747,648 | — | — | — |
Nautilus Biotechnology free cash flow growth trends
Over the last five reported fiscal years, free cash flow declined from −$14.9M to −$52.0M, a net decrease of $37.1M. Nautilus Biotechnology's latest reported quarter, Q1 2026, generated −$13.6M in free cash flow, an increase of $546,000 year over year.
About the metric
What free cash flow means
Free cash flow is the cash a company generates from operations after capital expenditures. Positive FCF can fund dividends, buybacks, debt repayment, or reinvestment; negative FCF means capital spending exceeded operating cash flow for that period.
Calculation and source
How free cash flow is calculated
TickerStat calculates free cash flow as SEC-reported operating cash flow minus capital expenditures. FCF margin equals free cash flow divided by revenue. Fiscal periods can differ from calendar years, so the tables include exact period-end dates.
Review Nautilus Biotechnology filings at SEC.gov ↗